Aquestive Therapeutics, Inc. logo AQST - Aquestive Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 10
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $9.00 DETAILS
HIGH: $12.00
LOW: $6.00
MEDIAN: $9.00
CONSENSUS: $9.00
UPSIDE: 118.45%
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue
Revenue 44.5 57.6 50.6 47.7 50.8 45.8 52.6 67.4 66.9 51.8
Cost of Revenue 17.2 17.9 20.8 19.4 15.0 13.0 20.4 21.0 19.8 16.4
Gross Profit 27.4 39.7 29.8 28.3 35.8 32.9 32.2 46.4 47.1 35.4
Operating Expenses
R&D Expenses 17.2 20.3 13.1 17.5 17.0 19.9 20.6 23.1 22.1 15.4
SG&A Expenses 79.8 50.2 31.8 52.9 53.5 55.9 64.3 72.3 25.1 20.8
Other Expenses 0 0 0 0 0 0 0 (0.0) 0 (0.1)
Operating Expenses 97.0 70.5 44.9 70.4 70.5 75.8 84.9 95.4 47.2 36.3
Operating Income
Operating Income (69.7) (30.8) (15.1) (42.1) (34.7) (42.9) (52.7) (48.9) (0.1) (0.8)
Interest Expense 17.1 16.8 7.5 12.4 22.5 13.0 9.3 7.7 7.7 6.1
Interest Income 0 3.4 16.3 0.1 0.4 0.1 0.6 0.6 0 0
Profitability
EBITDA (69.1) (26.6) 1.2 (39.6) (45.1) (39.2) (53.9) (50.3) 2.6 2.9
EBIT (69.7) (27.3) (0.2) (42.0) (48.1) (42.8) (56.9) (53.7) (1.2) (3.5)
Income Before Tax (83.8) (44.2) (7.6) (54.4) (70.5) (55.8) (66.2) (61.4) (8.9) (9.6)
Income Tax Expense 0 (0.0) 0.2 0 0 0 0 0 0 0
Net Income (83.8) (44.1) (7.9) (54.4) (70.5) (55.8) (66.2) (61.4) (8.9) (9.6)
Per Share Data
EPS (Basic) -0.76 -0.51 -0.13 -1.12 -1.85 -1.66 -2.87 -2.96 -0.45 -0.39
EPS (Diluted) -0.76 -0.51 -0.13 -1.12 -1.85 -1.66 -2.87 -2.96 -0.45 -0.39
Shares Outstanding 122.0 86.7 61.3 48.7 38.1 33.7 25.4 20.7 20 24.5
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Current Assets
Cash & Cash Equivalents 121.2 71.5 23.9 27.3 28.0 31.8 49.3 60.6 17.4 9.2
Short-Term Investments 0 0 0 0 0 0 0 0 0 0
Net Receivables 17.8 7.3 8.5 4.7 12.1 7.0 13.1 6.5 6.2 10.8
Inventory 6.2 6.0 6.8 5.8 4.0 2.5 2.9 5.4 4.0 2.9
Other Current Assets 4.2 3.3 1.9 2.1 0 0 0 1.7 0 0.1
Total Current Assets 149.3 88.2 41.0 39.9 47.3 44.6 68.3 74.2 28.2 23.3
Non-Current Assets
Property, Plant & Equipment 8.5 9.0 9.7 9.3 7.8 10.3 9.7 12.2 13.5 15.1
Goodwill 0 0 0 0 0 0 0.3 0 0 0
Intangible Assets 0 0 1.3 1.4 0.1 0.1 0.2 0.2 0.3 0.3
Long-Term Investments 2 3 4 0 6 0 0 0 0 0
Other Non-Current Assets 0.6 1.2 1.4 6.5 6.9 7.8 0 0.2 1.2 0.6
Total Non-Current Assets 11.2 13.2 16.5 17.2 14.7 18.3 10.2 12.7 15.0 16.1
Total Assets 160.4 101.4 57.4 57.1 62.0 62.9 78.5 86.9 43.1 39.4
Current Liabilities
Account Payables 29.9 10.3 8.9 9.9 8.3 7.1 12.3 20.4 9.6 6.6
Short-Term Debt 11.6 0.0 0.0 18.7 2.0 2.6 0 4.6 0 0
Deferred Revenue 1.1 1.0 1.6 1.5 0.8 0.7 0.8 0.7 1.3 0.8
Other Current Liabilities 5.0 1 5.1 7.5 7.2 7.8 1.7 3.6 0.6 0
Total Current Liabilities 47.6 18.9 18.3 39.5 22.0 21.1 18.6 33.0 15.3 10.8
Non-Current Liabilities
Long-Term Debt 115.5 32.5 27.5 33.4 51.6 34.3 60.3 42.6 45.5 38.6
Deferred Tax Liabilities 0 0 0 0 59.1 0 0 0 0 0
Other Non-Current Liabilities 7.3 85.2 80.3 66.1 2.5 49.5 1.4 1.2 8.8 7.5
Total Non-Current Liabilities 146.5 142.7 145.6 136.1 122.2 90.3 66.0 43.8 54.3 46.2
Total Liabilities 194.1 161.6 163.9 175.6 144.1 111.4 84.6 76.8 69.6 57.0
Stockholders' Equity
Common Stock 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 12.7 11.2
Retained Earnings (447.0) (363.2) (319.1) (311.2) (256.8) (186.3) (130.5) (61.4) (120.1) (108.7)
Accumulated Other Comprehensive Income 0 0 0 0 0 0 0 (35.2) (32.0) (28.3)
Total Stockholders' Equity (33.7) (60.2) (106.5) (118.6) (82.1) (48.5) (6.1) 10.1 (26.5) (17.6)
Total Liabilities & Equity 160.4 101.4 57.4 57.1 62.0 62.9 78.5 86.9 43.1 39.4
Debt Metrics
Total Debt 131.4 38.0 33.3 57.5 56.4 40.5 60.3 47.2 45.5 38.6
Net Debt 10.3 (33.5) 9.4 30.2 28.4 8.7 11.0 (13.4) 28.1 29.4
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Operating Activities
Net Income (83.8) (44.1) (7.9) (54.4) (70.5) (55.8) (66.2) (61.4) (8.9) (9.6)
Depreciation & Amortization 0.5 0.7 1.3 2.4 3.0 3.4 2.9 3.2 3.8 3.9
Stock-Based Compensation 7.6 7.1 2.7 4.4 6.8 6.6 7.1 29.9 0 0
Change in Working Capital 12.2 (10.0) (5.3) 32.0 (1.7) (4.4) (11.1) 8.0 7.9 (6.3)
Other Non-Cash Items 11.0 10.5 2.8 5.8 29.5 4.7 7.2 1.9 3.1 3.8
Operating Cash Flow (52.4) (35.8) (6.4) (9.8) (33.0) (45.5) (60.2) (13.0) 5.8 (8.2)
Investing Activities
Capital Expenditure (0.6) (0.2) (1.0) (2.5) (0.9) (0.5) (0.7) (1.8) (2.1) (1.0)
Acquisitions 0 0 0 0 0 0 0 0 0 0
Purchases of Investments 0 0 0 0 0 0 0 0 0 0
Sales/Maturities of Investments 0 0 0 0 0 0 0 0 0 1.2
Other Investing Activities 0 0 0 0 0 0 0 0 0 1.2
Investing Cash Flow (0.6) (0.2) (1.0) (2.5) (0.9) (0.5) (0.7) (1.8) (2.1) 0.2
Financing Activities
Net Debt Issuance (0.0) (0.0) (20.4) (2.0) 0 (22.5) 17.1 0 5 6.9
Stock Repurchased 0 0 0 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0 0
Other Financing Activities (0.8) (0.1) 15.4 0.0 0.3 44.7 (6.8) (10.8) (0.6) (1.2)
Financing Cash Flow 102.6 83.6 4.0 11.6 30.1 28.5 49.6 58.0 4.4 5.7
Cash Position
Net Change in Cash 49.6 47.7 (3.4) (0.8) (3.8) (17.5) (11.3) 43.2 8.2 (2.3)
Cash at Beginning 71.5 23.9 27.3 28.0 31.8 49.3 60.6 17.4 9.2 11.5
Cash at End 121.2 71.5 23.9 27.3 28.0 31.8 49.3 60.6 17.4 9.2
Free Cash Flow (53.0) (35.9) (7.4) (12.3) (33.9) (46.0) (60.9) (14.8) 3.8 (9.2)
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Income Statement
Revenue 44.5 57.6 50.6 47.7 50.8 45.8 52.6 67.4 66.9 51.8
Gross Profit 27.4 39.7 29.8 28.3 35.8 32.9 32.2 46.4 47.1 35.4
Operating Income (69.7) (30.8) (15.1) (42.1) (34.7) (42.9) (52.7) (48.9) (0.1) (0.8)
Net Income (83.8) (44.1) (7.9) (54.4) (70.5) (55.8) (66.2) (61.4) (8.9) (9.6)
EPS (Diluted) -0.76 -0.51 -0.13 -1.12 -1.85 -1.66 -2.87 -2.96 -0.45 -0.39
Balance Sheet
Cash & Equivalents 121.2 71.5 23.9 27.3 28.0 31.8 49.3 60.6 17.4 9.2
Total Assets 160.4 101.4 57.4 57.1 62.0 62.9 78.5 86.9 43.1 39.4
Total Debt 131.4 38.0 33.3 57.5 56.4 40.5 60.3 47.2 45.5 38.6
Stockholders' Equity (33.7) (60.2) (106.5) (118.6) (82.1) (48.5) (6.1) 10.1 (26.5) (17.6)
Cash Flow
Operating Cash Flow (52.4) (35.8) (6.4) (9.8) (33.0) (45.5) (60.2) (13.0) 5.8 (8.2)
Capital Expenditure (0.6) (0.2) (1.0) (2.5) (0.9) (0.5) (0.7) (1.8) (2.1) (1.0)
Free Cash Flow (53.0) (35.9) (7.4) (12.3) (33.9) (46.0) (60.9) (14.8) 3.8 (9.2)